Skip to Content

Pentosan Polysulfate Sodium

Pronunciation: PEN-toe-san
Class: Interstitial cystitis agent

Trade Names

- Capsules 100 mg


Unknown. Adheres to and may protect the mucosal membrane of the bladder.

Slideshow: The Shocking Truth About Antibiotic Resistance



Absorption is approximately 3% of dose.


Distributed to the uroepithelium of the GU tract with lesser amounts in liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low.


68% of dose undergoes desulfation in liver and spleen 1 h after IV administration; partial depolymerization occurs in the kidney.


Renal excretion is 3% as unchanged drug. The t ½ is 24 h (IV) and 4.8 h (oral).

Indications and Usage

For relief of bladder pain or discomfort associated with interstitial cystitis.


Standard considerations.

Dosage and Administration


PO 100 mg 3 times daily.


Store at room temperature (68° to 77°F) in tightly closed container.

Drug Interactions

Anticoagulants, antiplatelet agents, thrombolytics

Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet, or thrombolytic drugs.

Laboratory Test Interactions

None reported.

Adverse Reactions


Headache; emotional lability; depression; dizziness.


Alopecia; rash.


Nausea; abdominal pain; diarrhea; dyspepsia.


Liver function abnormalities.



Category B .




Safety and efficacy not established.

Anticoagulant effects

Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps, or diverticula before initiating therapy.

Hepatic/Splenic function impairment

Use with caution.


Use with caution in patients with a history of heparin-induced thrombocytopenia.



Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities.

Patient Information

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium at least 1 h before or 2 h after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with health care provider before taking any other medications including OTCs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider at least every 3 mo to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform health care provider if noted.
  • Instruct patient to inform health care provider if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if experiencing jaundice or other signs of liver disease.

Copyright © 2009 Wolters Kluwer Health.